Investing.com - Autolus Therapeutics (NASDAQ: AUTL) reported first quarter EPS of $-0.170, $0.10 better than the analyst estimate of $-0.269. Revenue for the quarter came in at $4.5M versus the consensus estimate of $11.18M.
Autolus Therapeutics's stock price closed at $1.910. It is down -36.120% in the last 3 months and down -48.770% in the last 12 months.
Autolus Therapeutics saw 3 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Autolus Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Autolus Therapeutics's Financial Health score is "weak performance".
Check out Autolus Therapeutics's recent earnings performance, and Autolus Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar